SEC Form 4 · accession 0001770749-26-000003
Guardant Health, Inc. · GH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Meghan V. Joyce
Director
Period of report
Jun 3, 2026
Accepted (ET)
Jun 4, 2026 · 6:07 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001576280
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 3, 2026 | M | 1,197 | $38.42 | A | 12,380 | D | |
| Common Stock | Jun 3, 2026 | M | 8,803 | $38.005 | A | 21,183 | D | |
| Common StockF1 | Jun 3, 2026 | S | 3,516 | $126.5157 | D | 17,667 | D | |
| Common StockF2 | Jun 3, 2026 | S | 5,728 | $127.1054 | D | 11,939 | D | |
| Common StockF3 | Jun 3, 2026 | S | 650 | $128.0196 | D | 11,289 | D | |
| Common StockF4 | Jun 3, 2026 | S | 106 | $129.3111 | D | 11,183 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F5 | $38.42 | Jun 3, 2026 | M | 1,197 | D | — | Jun 14, 2032 | Common Stock | 1,197 | 7,908 | D |
| Stock Option (Right to Buy)F6 | $38.005 | Jun 3, 2026 | M | 8,803 | D | — | Jun 14, 2033 | Common Stock | 8,803 | 0 | D |
Explanation of responses
- F1Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $125.80 to $126.785. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- F2Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $126.815 to $127.75. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $127.92 to $128.24. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.28 to $129.83. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5The stock option award vested in full on June 14, 2023.
- F6The stock option award vested in full on June 12, 2024.